Last updated: May 25, 2026
Zuranolone supply chains split into (1) drug substance (API) and (2) finished-dose manufacturing. The practical supplier set is defined by the companies that hold the Drug Master Files (DMFs) and by the contract manufacturing organizations (CMOs) that build the FDA-approved product and any line-extended dosage forms. Without a specific FDA label product (strength and dosage form) and without Orange Book/DMF-level sourcing details, the supplier list cannot be stated as a fact.
Zuranolone supply chain: who makes the drug substance (API) and where are DMFs filed?
What determines “zuranolone suppliers” in practice
- API suppliers are identified through FDA DMFs for zuranolone, typically cross-referenced in CMC sections of the NDA/BLA and in FDA labeling when available.
- Finished-dose suppliers are identified through manufacturing site disclosures in FDA approval documents, label “Manufactured for/By” sections, and CMC listings associated with the approved NDA.
API (drug substance) vs finished product (drug product)
- Zuranolone API supplier selection impacts purity specs, genotoxic impurity profiles, and polymorph control.
- Finished-dose manufacturing controls blend uniformity, moisture sensitivity, and dissolution performance, which then drive formulation IP and stability requirements.
Key manufacturing roles to map
- DMF holder(s) for zuranolone (API)
- Contract manufacturing site(s) for drug substance
- Contract manufacturing site(s) for drug product (capsules/tablets and any other dosage forms)
- Fill-finish partners (if separate from drug product manufacturing)
- Packaging and labeling vendors (secondary, but relevant for supply continuity)
How strong is the supplier base: is there multi-site manufacturing or single-source risk?
- Single-site drug product manufacturing increases outage risk and can become a bottleneck in Phase 3 scale-up or post-approval demand spikes.
- Multi-site capacity reduces lead times and supports incremental regulatory filings if sites are qualified through comparable process validation.
What companies supply zuranolone API (drug substance) for NDA/commercial supply?
Featured answer
A defensible, company-named supplier list for zuranolone cannot be produced from the information available in this prompt.
What you can conclude from standard FDA sourcing
- The API supply chain for an FDA-approved CNS product typically uses one primary DMF route for the core compound, plus secondary routes for redundancy.
- If there is only one DMF, the supplier set is effectively single-source for that route unless an approved comparability package exists for an alternative API manufacturer.
Which CMOs manufacture zuranolone capsules/tablets (drug product) for commercial supply?
Featured answer
A fact-based CMO list for zuranolone cannot be provided without confirmed label/approval-document “manufactured by” and/or CMC manufacturing-site disclosures.
What matters for CMO selection in zuranolone
- Controlled substances status is not, by itself, a “supply” indicator. The operational constraints are controlled compound handling, chain-of-custody logistics, and secure warehousing at fill-finish.
- For CNS products, stability and dissolution performance can require specific excipient sourcing and tighter atmospheric/moisture control.
Does zuranolone use different suppliers across strengths, formulations, or packaging formats?
Featured answer
A cross-strength and cross-format supplier map cannot be stated as fact here.
Why supplier variation occurs
- Different strengths can use different batch sizes, line equipment, or scale-up blends.
- Changes in capsule composition, fill weight, or coating systems can drive site requalification.
- Packaging line changes (bottles vs blister, unit-dose formats) can shift fill-finish vendors even when the API supplier is constant.
Which filings reveal zuranolone manufacturing sites: NDA, amendments, annual reports, and CMC supplements?
Featured answer
A cited mapping of zuranolone manufacturing sites to specific companies requires primary record citations (FDA approval letter, label, and/or database excerpts), which are not present in the supplied information.
Where site identities are typically disclosed
- FDA label “Manufactured for” and “Manufactured by” sections
- CMC module manufacturing site listings
- Approval documents for post-approval changes and supplements
How to benchmark supplier lead times and supply continuity for zuranolone API and drug product
Practical benchmarking signals
- Number of qualified manufacturing sites
- History of FDA CMC supplement approvals tied to manufacturing changes
- Public supply disruptions or distribution constraints in the first 12 to 24 months post-launch
What generic or biosimilar programs imply about supplier dependencies
- Even for small-molecule products like zuranolone, generic development depends on API access plus formulation know-how.
- A generic supplier that cannot secure API supply tends to wait for a viable DMF or to qualify an alternative API route, which can slow Paragraph IV readiness.
What patent/IP barriers affect supplier substitution for zuranolone?
A supplier list is separate from patent scope, but supplier substitution often runs into:
- Process patents for synthesis and impurity profiles
- Solid-state patents for specific forms or mixtures (if protected)
- Formulation patents for release/dissolution behavior
- Analytical method IP that affects comparability
How strong is the patent estate for supplier substitution risk?
Not addressed in this prompt with patent identifiers, jurisdiction, or Orange Book listings. A supplier substitution risk analysis cannot be completed as a fact without the underlying patent and regulatory record.
When do supplier constraints tighten: launch ramp, annual demand seasonality, or scale-up?
Not determinable without commercial demand data and manufacturing history.
Key Takeaways
- Zuranolone supplier identification (API and drug product) requires confirmed DMF holders and manufacturing-site disclosures from FDA records or approved labeling.
- This prompt does not contain the primary sourcing data needed to name API suppliers or CMOs as facts.
- Supplier risk analysis (single-site dependency, lead time constraints, and change-control burden) also requires manufacturing history and site multiplicity data that are not included here.
FAQs
- How do you identify zuranolone API suppliers from FDA records?
- What manufacturing sites are typically listed for zuranolone in FDA labeling and CMC documents?
- Can the same company supply both zuranolone API and drug product (fill-finish) for commercial batches?
- What factors cause zuranolone supplier switches between strengths or packaging formats?
- How do DMF holders influence zuranolone generic launch timelines?
References
(No cited sources provided in the prompt.)
